Phathom Pharmaceuticals Inc (PHAT)


Stock Price Forecast

March 28, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Phathom Pharmaceuticals Inc chart...

About the Company

phathom pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. the company has the rights in the united states, europe, and canada to vonoprazan, a potassium-competitive acid blocker (p-cab) that blocks acid secretion in the stomach. it is also developing vonoprazan, which is in phase iii clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of helicobacter pylori infection. the company was incorporated in 2018 and is based in buffalo grove, illinois.

Exchange

NASDAQ

Website

phathompharma.com

$M

Total Revenue

105

Employees

$616M

Market Capitalization

-2.97

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $PHAT News

Phathom Pharma launches campaign ‘VOQUEZNA Can Kick Some Acid’ to raise awareness on treatment option vonoprazan

1d ago, source: Pharmabiz

Phathom Pharma launches campaign ‘VOQUEZNA Can Kick Some Acid’ to raise awareness on treatment option vonoprazan: Florham Park, New Jersey Thursday, March 28, 2024, 18:00 Hrs ...

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2023 Earnings Call Transcript

20d ago, source: Hosted on MSN

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2023 Earnings Call Transcript March 7, 2024 Phathom Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.8, expectations were $-0.92.

PHAT Phathom Pharmaceuticals, Inc.

1d ago, source: Seeking Alpha

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States ...

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, "VOQUEZNA Can Kick Some Acid"

3d ago, source: Stockhouse

FLORHAM PARK, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for ...

Phathom Pharmaceuticals CEO sells shares worth over $153,000

2d ago, source: Investing

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) President and Chief Executive Terrie Curran has sold a total of 16,851 shares of the company's common stock, according to a recent filing with the ...

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

22d ago, source: Business Insider

Launched VOQUEZNA® (vonoprazan) tablets in November 2023 for the treatment of Erosive GERD (gastroesophageal reflux disease), achieving net revenu ...

Phathom Pharmaceuticals Inc Ordinary shares

28d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

3d ago, source:

A Media Snippet accompanying this announcement is available by clicking on this link.FLORHAM PARK, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- ...

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2023 Earnings Call Transcript

21d ago, source: Seeking Alpha

Hello and welcome to the Phathom Pharmaceuticals Fourth Quarter and Full Year 2023 Earnings Conference Call. [Operator Instructions] Please be advised today's conference is being recorded.

Q4 2023 Phathom Pharmaceuticals Inc Earnings Call

21d ago, source: Yahoo Finance

Eric Sciorilli; Head of IR; Phathom Pharmaceuticals, Inc. Terrie Curran; President & CEO; Phathom Pharmaceuticals, Inc. Martin Gilligan; Chief Commercial Officer ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...